Risk factors and survival outcomes in patients with brain metastases from breast cancer

Clinical and Experimental Metastasis

Volumn 30, Issue 8, 2013, Pages 951-956

  Minisini, A M ^a   Moroso, S ^a   Gerratana, L ^a   Giangreco, M ^b   Iacono, D ^a   Poletto, E ^a   Guardascione, M ^a   Fontanella, C ^a   Fasola, G ^a   Puglisi, F ^a,b  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

Brain metastases; Breast cancer; Immunophenotype; Prognostic factors; Risk factors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CENTRAL NERVOUS SYSTEM METASTASIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; RETROSPECTIVE STUDY; RISK FACTOR; TUMOR INVASION;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84890440392     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-013-9594-5     Document Type: Article

References (26)

1. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69-90. doi: 10.3322/caac.20107
2. Giordano SH, Buzdar AU, Smith TL et al (2004) Is breast cancer survival improving? Cancer 100:44-52. doi: 10.1002/cncr.11859
3. Kennecke H, Yerushalmi R, Woods R et al (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271-3277. doi: 10.1200/JCO.2009.25.9820
4. DiStefano A, Yong Yap Y, Hortobagyi GN, Blumenschein GR (1979) The natural history of breast cancer patients with brain metastases. Cancer 44:1913-1918
5. Niwińska A, Murawska M, Pogoda K (2010) Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 21:942-948. doi: 10.1093/annonc/mdp407
6. Berghoff A, Bago-Horvath Z, De Vries C et al (2012) Brain metastases free survival differs between breast cancer subtypes. Br J Cancer 106:440-446. doi: 10.1038/bjc.2011.597
7. Kim H-J, Im S-A, Keam B et al (2012) Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. J Neurooncol 106:303-313. doi: 10.1007/s11060-011-0664-8
8. Lee YT (1983) Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol 23:175-180
9. Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. J Neurooncol 75:5-14. doi: 10.1007/s11060-004-8093-6
10. Posner JB (1992) Management of brain metastases. Rev Neurol (Paris) 148:477-487
11. Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22:3608-3617. doi: 10.1200/JCO.2004.01.175
12. Heitz F, Harter P, Lueck H-J et al (2009) Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 45:2792-2798. doi: 10.1016/j.ejca.2009.06.027
13. Lin NU, Claus E, Sohl J et al (2008) Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113:2638-2645. doi: 10.1002/cncr.23930
14. Pestalozzi BC, Zahrieh D, Price KN et al (2006) Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 17:935-944. doi: 10.1093/annonc/mdl064
15. Hicks DG, Short SM, Prescott NL et al (2006) Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 30:1097-1104. doi: 10.1097/01.pas.0000213306.05811.b9
16. Graesslin O, Abdulkarim BS, Coutant C et al (2010) Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol 28:2032-2037. doi: 10.1200/JCO.2009.24.6314
17. Minn AJ, Gupta GP, Padua D et al (2007) Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci USA 104:6740-6745. doi: 10.1073/pnas.0701138104
18. Bos PD, Zhang XH-F, Nadal C et al (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459:1005-1009. doi: 10.1038/nature08021
19. Heitz F, Rochon J, Harter P et al (2011) Cerebral metastases in metastatic breast cancer: disease-specific risk factors and survival. Ann Oncol 22:1571-1581. doi: 10.1093/annonc/mdq625
20. Weil RJ, Palmieri DC, Bronder JL et al (2005) Breast cancer metastasis to the central nervous system. Am J Pathol 167:913-920. doi: 10.1016/S0002- 9440(10)61180-7
21. Crivellari D, Pagani O, Veronesi A et al (2001) High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 12:353-356
22. Park YH, Park MJ, Ji SH et al (2009) Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer 100:894-900. doi: 10.1038/sj.bjc.6604941
23. Le Scodan R, Jouanneau L, Massard C et al (2011) Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. BMC Cancer 11:395. doi: 10.1186/1471-2407-11-395
24. Sperduto PW, Kased N, Roberge D et al (2012) Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys 82:2111-2117. doi: 10.1016/j.ijrobp.2011.02.027
25. Sperduto PW, Kased N, Roberge D et al (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30:419-425. doi: 10.1200/JCO.2011.38.0527
26. Sperduto PW, Kased N, Roberge D et al (2013) The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. J Neurooncol 112:467-472. doi: 10.1007/s11060-013-1083-9